Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: a linked national survey and administrative claims database study

Objective To characterize burden of migraine in prevention-eligible patients compared with prevention non-eligible patients in the United States (US). Receipt of preventive therapy was also examined among prevention-eligible patients. Methods This retrospective study utilized data from the 2017 US National Health and Wellness Survey linked with medical and pharmacy claims. Patients aged >= 18 years who self-reported experiencing migraine and had confirmed evidence of migraine (>= 1 medical or pharmacy claim) were included. Prevention eligibility was based on number of headache days in the past 30 days (prevention-eligible: >= 4 and prevention non-eligible: <4). Descriptive statistics summarized study variables; bivariate and multivariable analyses were conducted to examine the association of prevention-eligibility status with outcomes. Results Analyses included 450 patients, 291 (65%) prevention-eligible, and of these 56 (19%) received preventive therapy. Overall, patients were 42.98 +/- 14.51 years old; 84% were female. Prevention-eligible patients reported significantly more migraine headache days in the past 6 months (29.27 +/- 37.96 vs. 8.61 +/- 7.88), had lower mental component summary scores (35.80 +/- 2.73 vs. 37.90 +/- 2.96), and more presenteeism (47.30 +/- 2.98% vs. 37.90 +/- 2.60%), overall work impairment (46.30 +/- 2.87% vs. 37.90 +/- 2.55%) and activity days missed due to migraine (8.16 +/- 3.05 vs. 3.82 +/- 1.58) than prevention non-eligible patients (all p<.001). Prevention-eligible patients receiving preventive therapy reported more migraine headache days during the past month (9.21 +/- 7.99 vs. 6.06 +/- 7.10; p=.002) and activity days lost due to migraine (18.39 +/- 28.08 vs. 10.69 +/- 21.43, p=.015) than those not receiving preventive therapy. Conclusions Prevention-eligible patients experience greater burden due to migraine, including more headache days, worse health-related quality-of-life, and greater work and activity impairment than prevention non-eligible patients.